Pharmacy costs of specialty medications for plaque psoriasis in the United States

J Am Acad Dermatol. 2019 Jan;80(1):274-275. doi: 10.1016/j.jaad.2018.04.019. Epub 2018 Apr 16.

Authors

Eric J Yang¹, Kristen M Beck², Sahil Sekhon², Tina Bhutani²

Affiliations

¹ Department of Dermatology, University of California San Francisco, San Francisco, California; Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois. Electronic address: ericjyang@outlook.com.
² Department of Dermatology, University of California San Francisco, San Francisco, California.

PMID: 29673778
DOI: 10.1016/j.jaad.2018.04.019

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / economics
Adalimumab / therapeutic use
Anti-Inflammatory Agents / economics*
Anti-Inflammatory Agents / therapeutic use
Cost of Illness*
Dermatologic Agents / economics*
Dermatologic Agents / therapeutic use
Etanercept / economics
Etanercept / therapeutic use
Humans
Psoriasis / drug therapy
Psoriasis / economics*
Thalidomide / analogs & derivatives
Thalidomide / economics
Thalidomide / therapeutic use
Time Factors
United States
Ustekinumab / economics
Ustekinumab / therapeutic use

Substances

Anti-Inflammatory Agents
Dermatologic Agents
Thalidomide
Ustekinumab
Adalimumab
Etanercept
apremilast